A 12-Week, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Buprenorphine HCl in Subjects With Moderate to Severe Chronic Low Back Pain.
Phase of Trial: Phase III
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Buprenorphine (Primary)
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Sponsors Endo Pharmaceuticals
- 28 Sep 2011 Primary endpoint 'Pain-intensity' has not been met, according to a BioDelivery Sciences media release.
- 27 Jul 2011 Status changed from active, no longer recruiting to completed.
- 05 Apr 2011 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History